StockData
Autolus Therapeutics plc logo

Autolus Therapeutics plc (AUTL) stock

AUTLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/3019% below fair value
$1.14−0.03 (-2.56%)

Close on Nov 16, 2026Market cap $303.43MP/E –Yield –

Autolus Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Autolus Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was -$238.85M. For fiscal 2025 it was -$262.25M. The highest annual figure on record is -$132.59M in fiscal 2021.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$262.25M–
FY2024Dec 31, 2024-$233.87M–
FY2023Dec 31, 2023-$173.14M–
FY2022Dec 31, 2022-$135.99M–
FY2021Dec 31, 2021-$132.59M–
FY2020Dec 31, 2020-$162.49M–

Quarterly ebitda

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2026CQ2 2026Jun 30, 2026-$41.68M–
Q1 FY2026CQ1 2026Mar 31, 2026-$57.30M–
Q4 FY2025CQ4 2025Dec 31, 2025-$70.32M–
Q3 FY2025CQ3 2025Sep 30, 2025-$69.54M–
Q2 FY2025CQ2 2025Jun 30, 2025-$59.13M–
Q1 FY2025CQ1 2025Mar 31, 2025-$63.25M–
Q4 FY2024CQ4 2024Dec 31, 2024-$73.95M–
Q3 FY2024CQ3 2024Sep 30, 2024-$65.94M–
Q2 FY2024CQ2 2024Jun 30, 2024-$57.03M–
Q1 FY2024CQ1 2024Mar 31, 2024-$36.95M–
Q4 FY2023CQ4 2023Dec 31, 2023-$51.50M–
Q3 FY2023CQ3 2023Sep 30, 2023-$41.53M–
Q2 FY2023CQ2 2023Jun 30, 2023-$42.87M–
Q1 FY2023CQ1 2023Mar 31, 2023-$37.25M–
Q4 FY2022CQ4 2022Dec 31, 2022-$10.00M–
Q1 FY2021CQ1 2021Mar 31, 2021-$38.21M–
Q4 FY2020CQ4 2020Dec 31, 2020-$45.67M–
Q3 FY2020CQ3 2020Sep 30, 2020-$41.24M–
Q2 FY2020CQ2 2020Jun 30, 2020-$38.28M–
Q1 FY2020CQ1 2020Mar 31, 2020-$37.30M–

More Autolus Therapeutics figures

See a number that looks wrong?